发明公开
- 专利标题： CRKL TARGETING PEPTIDES
- 专利标题（中）： 目标END CRKL肽
-
申请号： EP09767865.0申请日： 2009-06-19
-
公开(公告)号： EP2303913A2公开(公告)日： 2011-04-06
- 发明人: ARAP, Wadih , MINTZ, Paul, J. , PASQUALINI, Renata
- 申请人： The Board of Regents of The University of Texas System
- 申请人地址： 201 West 7th Street Austin, TX 78701 US
- 专利权人： The Board of Regents of The University of Texas System
- 当前专利权人： The Board of Regents of The University of Texas System
- 当前专利权人地址： 201 West 7th Street Austin, TX 78701 US
- 代理机构： Vossius & Partner
- 优先权： US74423P 20080620
- 国际公布： WO2009155556 20091223
- 主分类号： C07K7/08
- IPC分类号： C07K7/08 ; C07K7/06 ; A61K38/10 ; A61P35/00
摘要：
Provided are methods and compositions for selectively targeting CRKL through the use of targeting peptides. Selective targeting of secreted CRKL through the use of a targeting peptide may be used, for example, in the treatment of cancer to deliver a chemotherapeutic compound, fusion protein, or fusion construct to a cancer cell or tissue.
信息查询
